Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as hMN14 (labetuzumab)
hMN14 · 3 trials · 9 indications
| Name | Type | Description |
|---|---|---|
| hMN14 (labetuzumab) | DRUG | - |
Disease Characteristics: * Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma * Measurable lesion diagnosed by CT scan * Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: * Chemotherapy: Patients who either have failed at lea...
Top 20 of 80 competitors
hMN14 is an investigational monoclonal antibody developed by Gilead Sciences, Inc. (ticker GILD). It has been studied in Phase 1 clinical trials for colorectal cancer and pancreatic neoplasms. It is also known as labetuzumab. The trials were completed, and no active trials are currently listed.
hMN14 has been studied in Phase 1 trials for colorectal cancer and pancreatic neoplasms. One trial evaluated hMN14 in colorectal and breast cancer, another evaluated 90Y-hMN14 in pancreatic cancer, and a third evaluated 90Y-hMN14 in colorectal cancer. It is investigational and not approved for commercial use.
Gilead Sciences, Inc. is the developer of hMN14. The company trades under the ticker GILD. Gilead sponsored the Phase 1 clinical trials of hMN14 in colorectal cancer and pancreatic neoplasms.
hMN14 is in Phase 1 clinical development. All listed trials are Phase 1 and have been completed. There are no active trials. hMN14 is investigational and has not been approved by the FDA for any indication.
hMN14 has been studied in completed Phase 1 trials: NCT00041652 evaluated hMN14 in colorectal and breast cancer with 30 participants, NCT00041639 evaluated 90Y-hMN14 in pancreatic cancer with 75 participants, and NCT00040599 evaluated 90Y-hMN14 in colorectal cancer with 72 participants.
Yes, hMN14 is also known as labetuzumab. Both names refer to the same investigational monoclonal antibody developed by Gilead Sciences, Inc. (ticker GILD) and studied in Phase 1 trials for colorectal cancer and pancreatic neoplasms.